Where gene fragment synthesis beats cloning and where it quietly fails: how custom gene synthesis, artificial gene synthesis, synthetic genes generally and dna fragment synthesis are quoted per base while difficulty is priced in lead time, what makes a sequence hard enough to be refused, why gene synthesis and cloning as a package often costs less than a fragment plus your own assembly, what codon choices do and do not buy in a given host, where cdna synthesis answers a different question entirely, and what enzymatic dna synthesis, or enzymatic synthesis as the field is coming to call it, changes about the sequences that can be made at all
Synthesis has become cheap enough that building a construct by hand is often the more expensive option, but the price per base hides the part that matters: whether your particular sequence is easy or hard to make. Repeats, extreme composition and structure turn a routine order into a quotation with a long lead time or a refusal. This page is about anticipating that before the order.
- good laboratory practice for nonclinical studies, 21 CFR
- Part 58
- the biosafety manual that decides containment for recombinant constructs
- BMBL
- electronic records and signatures, the clause behind a construct record
- Part 11
The figures in this panel are regulation and manual identifiers, named from the documents themselves and linked below. They are not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a synthesis price index beyond what it has measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Ordering well
- Screen the sequence for difficulty before ordering. Long repeats, homopolymer runs, extreme composition and strong secondary structure are what make synthesis slow or impossible. Suppliers screen automatically and will tell you, but finding out during quotation rather than after a delay is worth doing deliberately.
- Decide fragment or finished construct. A linear fragment is cheaper and leaves you the assembly. A sequence verified plasmid arrives ready to use and includes the cloning and the verification. Price the bench time before choosing the fragment, because the assembly is rarely free.
- Choose codon adaptation with a reason. Adapting codons to the expression host can raise yield substantially, and it can also remove regulatory elements, change folding kinetics or break an intended sequence feature. Adapt when expression is the goal, keep the native sequence when the sequence itself is under study.
- Specify the delivery format and the ends. Vector, insertion site, tags, overhangs and the exact junction sequences belong in the order, not in a follow up email. Most rework in this category comes from an assumed backbone or an assumed reading frame.
- Keep the verification evidence with the construct. Ask for the full sequence as manufactured and the underlying reads. File them against the construct identifier so the next person does not resequence a construct that was already verified.
What actually makes a sequence expensive
Synthesis assembles short pieces into longer ones, and anything that makes those pieces ambiguous to assemble raises the cost. Repeats are the worst case because identical regions cannot be ordered unambiguously; extreme composition and hairpins slow the chemistry and the verification.
If a design has a choice, designing away from these features early is far cheaper than discovering them at quotation. Suppliers will screen a draft sequence before an order is placed, and it costs nothing to ask.
Screening and legitimate use
Commercial synthesis providers screen orders against sequences of concern and confirm customer legitimacy, which is a routine part of ordering rather than an obstacle. Orders from a new institution or for an unusual sequence may take longer for that reason.
Plan for it in timelines and give the supplier the institutional details they ask for at the start. It is an entirely normal step and delays only those who are surprised by it.
Common questions
- Why was my sequence refused or delayed?
- Almost always structural difficulty: long repeats, extreme composition, homopolymer runs or strong secondary structure. Splitting the sequence, silently varying codons in the difficult region or accepting a longer lead time are the usual remedies.
- Should I always codon optimise?
- No. Optimise when the aim is protein yield in a known host. Keep the native sequence when regulatory elements, splicing, translational pausing or the sequence itself is part of what you are studying, because adaptation quietly removes those features.
- Is a fragment cheaper than a clone?
- Per base, yes. In total, frequently not, once assembly, transformation, screening and sequence verification are costed as labour. Fragments make sense when you are assembling several of them into something a supplier could not deliver anyway.
- How does synthesis compare with amplifying from cDNA?
- Amplification gives you the natural sequence including any variant present in your source, which is sometimes exactly what you want and sometimes a surprise. Synthesis gives you the sequence you specified, which is easier to defend and to reproduce.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/gene-fragment-synthesis/.